Código QR (código de barras bidimensional)

Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...

ver descrição completa

Na minha lista:
Principais autores: Karin Teppert, Nora Winter, Vera Herbel, Caroline Brandes, Simon Lennartz, Fabian Engert, Andrew Kaiser, Thomas Schaser, Dominik Lock
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-10-01
coleção:Frontiers in Immunology
Assuntos:
immunotherapy
adoptive T cell therapy
chimeric antigen receptor
chimeric costimulatory receptor
melanoma
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1178060/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados